Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483456 | 1.00 | ECE1 (0.36) | ECE1 | |
| SCHEMBL1633687 | 0.82 | MAPT (0.34) | — | |
| SCHEMBL17159700 | 0.82 | ECE1 (0.46) | ECE1 | |
| SCHEMBL27420074 | 0.82 | — | — | |
| SCHEMBL8234180 | 0.82 | ALDH1A1 (0.36) | — | |
| SCHEMBL17159699 | 0.82 | ECE1 (0.46) | ECE1 | |
| SCHEMBL13166781 | 0.82 | — | — | |
| SCHEMBL20117450 | 0.81 | KMT2A (0.35) | ECE1 | |
| SCHEMBL19483457 | 0.81 | KMT2A (0.35) | ECE1 | |
| Hydrochloric Acid SCHEMBL20789044 | 0.80 | ECE1 (0.45) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| US-20180052952-A9 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180052952-A9 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-02-22 | — | — | US | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-05-21 | — | — | US | disclosed |
| US-20140222398-A1 | METHODS AND APPARATUS FOR DOUBLE-INTEGRATION ORTHOGONAL SPACE TEMPERING | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8779090-B2 | Methods and compositions for the treatment of heart failure and other disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120283411-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2012-02-16 | — | — | US | disclosed |
| US-20110306125-A1 | Protein Expression Methods | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | Ironwood Pharmaceuticals Inc. | 2011-01-27 | — | — | US | disclosed |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | ECE1 783/4885 |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | ECE1 783/4885 |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 3617/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ECE1 47/4885 |
| US-20120283411-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 3617/4885 |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ECE1 47/4885 |
| US-20110306125-A1 | Protein Expression Methods | GUCY1B2, GUCY1A2, GUCY1B1 | ECE1 2755/4885 |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 2868/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | ECE1 2915/4885 |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GIPR, VIP, GCGR | ECE1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.